Casper Breum

Casper Breum

Fundador en
Sound Bioventures Management ApS
.
59 años
Health Technology
Finance
Miscellaneous

Perfil

Casper Breum is the founder of Sound Bioventures Management ApS, serving as Managing Partner since 2021.
Current jobs include Director at Sanifit Therapeutics SA since 2015, Director at VarmX BV since 2020, and Senior Advisor at Lundbeckfonden Ventures since 2021.
Former jobs include Chief Executive Officer at ilochip Bioscience A, Director at Asante Solutions, Inc., Director at Aura Biosciences, Inc., Director at Lundbeckfond Invest A, Director at Lundbeckfonden, Director at Nexstim Oyj, Director at DYSIS Medical Ltd. from 2013 to 2021, Director at Biom'Up SA, Director at Atox Bio Ltd. from 2017 to 2021, Director at Spero Therapeutics, Inc. from 2015 to 2018, Principal at Novo Nordisk A, and Manager-Business Development at H.
Lundbeck A. Education includes a graduate degree from Technical University of Denmark conferred in 1992 and an MBA from Technical University of Denmark conferred in 2001.

Cargos activos de Casper Breum

EmpresasCargoInicio
Consultor / Asesor 01/10/2009
Director/Miembro de la Junta 01/07/2015
Director/Miembro de la Junta 01/07/2020
Fundador 01/01/2021

Antiguos cargos conocidos de Casper Breum.

EmpresasCargoFin
Director/Miembro de la Junta 31/10/2021
Director/Miembro de la Junta 31/10/2021
SPERO THERAPEUTICS, INC. Director/Miembro de la Junta 21/09/2018
Director Ejecutivo 04/08/2010
AURA BIOSCIENCES, INC. Director/Miembro de la Junta -
Ver el detalle de la experiencia de Casper Breum.

Formación de Casper Breum.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

81

Relaciones de 1er grado

17

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas17

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Miscellaneous

Consumer Services

Health Technology

Health Technology

Electronic Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Finance

-40%: Ampliación de plazo extraordinaria
d
:
:
APROVECHAR LA PROMOCIÓN